



ASX ANNOUNCEMENT

30 December 2019

**Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

Dear Sir / Madam,

Notification under sections 708A(5)(e) and (6) of the Corporations Act 2001 (Cth)

CardieX has issued an Appendix 3B with respect to the issue of 36,363,637 ordinary shares (CDX) and 9,090,910 free 1 for 4 attaching listed options (CDXO) of the Company. This is the placement of shares and options to third parties as announced 20 December 2019 in return for \$1,000,000 in total funds raised.

As previously announced C2 Ventures Pty Limited ("C2V"), a related company of Executive Chairman Niall Cairns and CEO Craig Cooper's participation component of \$500,000 on the same terms (which brings the total placement to \$1,500,000), will be by way of a convertible loan, with the conversion into ordinary shares subject to shareholder approval at the next available shareholder meeting.

Details of the issue of shares are set out in the Appendix 3B lodged on the same day.

CardieX gives notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) that:

1. Under the issue, CardieX has issued 36,363,637 ordinary shares (CDX) at the issue price of \$0.0275 per share and 9,090,910 free 1 for 4 attaching listed options (CDXO), raising \$1,000,000 without disclosure to investors under Part 6D.2 of the Corporations Act; and
2. As at the date of this notice:
 - (a) CardieX has complied with the provisions of Chapter 2M of the Act;
 - (b) CardieX has complied with section 674 of the Act; and
 - (c) there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

Yours faithfully,

A blue ink signature of Jarrod White, consisting of a stylized 'J' and 'W'.

Jarrod White
Company Secretary | Chief Financial Officer

jwhite@cardiex.com

Peter Taylor – NWR Communications
Investor Relations

peter@nwrcommunications.com.au

**About CardieX**

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" (cBP) which is considered essential for the management of hypertension and related cardiovascular disorders. XCEL was developed and is marketed by CardieX's 100% subsidiary, ATCOR.

CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.

In September 2019, the Company signed an agreement with Mobvoi, Google's partner in China, for the co-development of new wearable technologies and devices based on Mobvoi's smart watch products.